BU-NOT-SET

CONTACT US
Optimising formulation to improve solubility ready for Phase III
  • Drug product
Optimising formulation
Case study
Trends emerging in capsule dosage form development
  • Drug product
  • Industry trends
Capsules
Insight
Licensing portfolio
  • Corporate
containers
Fact sheet
Key trends in pharmaceutical outsourcing
  • Industry trends
Hands
Insight
The latest trends and innovations in oral drug delivery
  • Drug product
  • Industry trends
Pharma Roundtable
Insight
Recipharm invests in African vaccine production
  • Corporate
Building
Insight
The future of oral solid dose development and manufacturing
  • Drug product
  • Industry trends
Products
Insight
Sustainability Report 2021
  • Sustainability
Sustainability report
Report
Treating long-COVID with Erdosteine
  • Corporate
Treating long-COVID with Erdosteine
Insight
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies
Fact sheet
  • Analytical chemistry
Extractables & leachables testing
Insight
  • Industry trends
Pharmaceutical mergers and acquisitions: opportunities and drivers for CDMOs
Insight
  • Industry trends
Global expansion in the CDMO field
Fact sheet
  • Drug product
Fixed dose combinations - for improved patient compliance
Insight
  • Industry trends
The current state of contract manufacturing